Modality
Nanobody
MOA
JAK1i
Target
CD123
Pathway
Epigenetic
PsoriasisUC
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
Dec 2021
→ Aug 2026
NDA/BLACurrent
NCT07553451
1,254 pts·UC
2021-12→2026-08·Recruiting
1,254 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-114mo awayPh3 Readout· UC
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2026-08-11 · 4mo away
UC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07553451 | NDA/BLA | UC | Recruiting | 1254 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Zorizumab | Beam | Approved | CD123 | |
| Adagralucimab | Caribou Bio | NDA/BLA | CD123 |